European Heart Journal Advance Access originally published online on March 16, 2008
European Heart Journal 2008 29(8):957-958; doi:10.1093/eurheartj/ehn091
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org
Resistance to what, does it matter? How do we study it?
Department of Cardiology, Mayo Clinic, 200 First St S.W., Rochester, MN 55905, USA
* Corresponding author. Tel: +1 507 255 2504, Fax: +1 507 255 2550, Email: dholmes@mayo.edu
This editorial refers to Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
by M.J. Price et al., on page 992
Footnotes
The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
doi:10.1093/eurheartj/ehn046 ![]()
| The first 10% of the full text of this article appears below. |
The importance of platelets and thrombosis in the pathophysiology of acute ischaemic coronary syndromes has been well appreciated. This information has formed the backbone of the guidelines on both sides of the Atlantic that patients with acute as well as chronic coronary artery disease be treated with aspirin as a long-term strategy
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
- Matthew J. Price, Sarah Endemann, Raghava R. Gollapudi, Rafael Valencia, Curtiss T. Stinis, Justin P. Levisay, Alissa Ernst, Neil S. Sawhney, Richard A. Schatz, and Paul S. Teirstein
EHJ 2008 29: 992-1000.[Abstract] [Full Text]